INO Inovio Pharmaceuticals, Inc.
Inovio Pharmaceuticals, Inc. (INO) is expected to report earnings on November 11, 2026, after the market close. The consensus earnings estimate is a loss of $0.20 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of +34.6% since its last earnings release on August 12, 2026.
Sign in or subscribe to unlock sentiment, short interest, and technical indicators.
Whisperings™
About Inovio Pharmaceuticals, Inc.
Inovio Pharmaceuticals Inc is a clinical stage biopharmaceutical company. The Company develops active DNA immunotherapies and vaccines in combination with proprietary electroporation delivery devices to prevent and treat cancers and infectious diseases.
Sector
Healthcare
Industry
Biotechnology